Cellebrite DI, the Technology sector company, was revisited by a Wall Street analyst today. Analyst Mike Cikos from Needham maintained a Buy rating on the stock and has a $18.00 price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mike Cikos has given his Buy rating due to a combination of factors, starting with Cellebrite’s ability to exceed both its own guidance and market expectations while delivering solid annual recurring revenue growth, even when excluding the Corellium contribution. He also highlights that management’s 2026 outlook signals a renewed acceleration in ARR, with guidance implying high‑teens percentage growth that he interprets as a deliberately cautious baseline rather than a ceiling.
In his view, this guidance is underpinned by several growth drivers, including healthy demand, successful migration of customers to the Inseyets platform, and rising adoption of new offerings, all while the new CFO focuses on improving forecasting discipline and sustaining strong free‑cash‑flow margins. Cikos further views the planned acquisition of SCG Canada in drone forensics as an attractive, incremental upside that is not yet reflected in guidance, reinforcing his conviction in maintaining a Buy rating on CLBT.
According to TipRanks, Cikos is a 4-star analyst with an average return of 6.8% and a 45.66% success rate. Cikos covers the Technology sector, focusing on stocks such as MongoDB, Okta, and ServiceNow.